World Journal of
Pharmaceutical and Life Sciences

DEVELOPMENT OF A NOVEL GLP-1 BOOST CONTAINING NATURAL AGONISTS OF GLP-1 AND GIP AND INHIBITORS OF DPP-4 ENZYME FOR THE MANAGEMENT OF OBESITY AND GLUCOSE METABOLISM

Kedar N. Prasad* PhD

ABSTRACT

The prevalence of excess body weight, including obesity, and its associated risk of chronic diseases is increasing in the USA and worldwide.[1] In 2022, Centers for Disease Control and Prevention (CDC) estimated that at least 35% of adults in USA were living with obesity which increases the risk of type II diabetes. For decades, recommendations of consumption of diet low in fat and high in fiber with plenty of fruits and vegetables, reduce consumption of excess fat, carbohydrate, and caffeine, and regular physical exercise have failed to reduce weight or improve glucose metabolism because human behaviors with respect to diet and lifestyle are difficult to change. Consequently, the risk of obesity and excess weight as well as type II diabetes have increased. During 2021-2023, 40.3% Americans were obese (From CDC,2024) and in 2021, 11.61% (38.4 million had diabetes out of which 29.7% were diagnosed and 8.7 million were undiagnosed) (From National Institutes of Diabetes and Digestive and Kidney Diseases, 2024). Therefore, a novel strategy for the management of weight and improved glucose metabolism is needed. This major objective of this review is to briefly describe the discovery of two gut generated hormones GLP-1 and GIP which enhance glucose metabolism and weight loss. This review also describes history of development of synthetic and natural agonist of GLP-1 and GIP and their role in reducing obesity and improving glucose metabolism.

[Full Text Article]   [Download Certificate]